Nonattenuated Polymyxin B Used for the Treatment of Extreme-Drug Resistant Acinetobacter baumannii-Related Infections in Patients with Preexisting End Stage Renal Failure

Nonattenuated Polymyxin B Used for the Treatment of Extreme-Drug Resistant Acinetobacter baumannii-Related Infections in Patients with Preexisting End Stage Renal Failure

Recent pharmacokinetic studies have suggested that nonrenal clearance predominates the elimination of polymyxin B. We present 2 patients with preexisting end stage renal failure, who were given nonattenuated doses of polymyxin B for the treatment of extreme-drug resistant organism. No evidence of ad...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Case reports in infectious diseases 2014-01, Vol.2014 (2014), p.1-3
Hauptverfasser: Zhou, Yvonne Peijun, Chua, Nathalie Grace Sy, Chlebicki, Maciej Piotr, Lee, Winnie Hui Ling, Kwa, Andrea Lay Hoon
Format: Artikel
Sprache:eng
Schlagworte:
Antibiotics
Asthma
Case Report
Catheters
Drug dosages
Heart attacks
Hospitalization
Infections
Neurotoxicity
Pneumonia
Studies
Urine
Ventilators
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Recent pharmacokinetic studies have suggested that nonrenal clearance predominates the elimination of polymyxin B. We present 2 patients with preexisting end stage renal failure, who were given nonattenuated doses of polymyxin B for the treatment of extreme-drug resistant organism. No evidence of adverse events occurred and microbiological clearance was documented.
ISSN:2090-6625
2090-6633
DOI:10.1155/2014/573279